PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Ranibizumab - Retinal Vein Occlusion

PAD Profile : Ranibizumab - Retinal Vein Occlusion

Keywords :
RVO, CRVO, BRVO, biosimilar
Brand Names Include :
Lucentis, Ongavia, Ximluci, Byooviz, Rimmyrah

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Intravitreal injection
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
07 September 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed to support the use of biosimilar ranibizumab to the Surrey Heartlands Health economy in the following licensed indications, in line with the National commissioning recommendations following the national procurement for medical retinal vascular medicines

  • Wet Age-Related Macular degeneration (Wet AMD)
  • Central Retinal Vein Occlusion (CRVO)
  • Branch Retinal Vein Occlusion (BRVO)
  •  Diabetic Macular Oedema (DMO)
  • Myopic Choroidal Revascularisation (CNV)

Ranibizumab biosimilar should be used (in line with original NICE guidance) instead of the originator ranibizumab (Lucentis®) where this is clinically appropriate and there is capacity to do so. If ranibizumab biosimilar is contraindicated or not clinically appropriate for the specific patient or there are specific clinical considerations then, subject to the criteria specified in the relevant NICE technology appraisal guidance, clinicians should consider aflibercept, brolucizumab or faricimab.

Originator ranibizumab should not be used for new initiations

Clinicians should consider switching patients on originator ranibizumab to biosimilar ranibizumab with patient consent.

05 October 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends ranibizumab (Lucentis®) as a treatment option for the first line treatment of visual impairment caused by macular oedema secondary to branch or central retinal vein occlusion in line with NICE TA 283 (May 2013) and the NICE FAQ document relating to local formularies (link to document below). Ranibizumab will be considered RED on the traffic light system. NICE guidance TA283 was published in May 2013 for Ranibizumab for Macular Oedema (Retinal vein occlusion) and implementation of this guidance took place in August 2013.

Associated BNF Codes

11. Eye
11.08.02. Ocular diagnostic & peri-operative prepn & photodynamic tt
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More